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ABSTRACT 1 
 2 
Introduction: Lower Urinary Tract Symptoms (LUTS) is a bothersome condition affecting older men 3 
that can lead to poor quality of life. General Practitioners (GPs) currently have no easily available 4 
assessment tools to help effectively diagnose causes of LUTS and aid discussion of treatment with 5 
patients. Men are frequently referred to urology specialists who often recommend treatments that could 6 
have been initiated in Primary Care. GP access to simple, accurate tests and clinician decision tools are 7 
needed to facilitate accurate and effective patient management of LUTS in primary care.   8 
 9 
Methods and analysis: PriMUS is a prospective diagnostic accuracy study based in primary care. The 10 
study will determine which of a number of index tests used in combination, best predict three 11 
urodynamic observations in men who present to their GP with LUTS. These are detrusor overactivity, 12 
bladder outlet obstruction, and/or detrusor underactivity. Two cohorts of participants, one for 13 
development of the prototype diagnostic tool, and one for validation, will undergo a series of simple 14 
index tests and the invasive reference standard (invasive urodynamics). We will develop and validate 15 
three diagnostic prediction models based on each condition, and then combine them with management 16 
recommendations to form a clinical decision support tool.  17 
 18 
Ethics and dissemination: Ethics approval is from the Wales Research Ethics Committee 6. Findings 19 
will be disseminated through peer-reviewed journals and conferences; results will be of interest to 20 
professional and patient stakeholders.  21 
 22 
Study registration: ISRCTN10327305 23 
 24 
Strengths and limitations of this study 25 
 Prospective, multicentre study in an appropriate population in primary care. 26 
 The index tests are tests that can be done routinely in primary care or at home by patients. 27 
 The diagnostic models developed will be validated in a separate cohort of men from the same 28 
population. 29 
 The assumed prevalence of the three target conditions may be different in practice. 30 
 Some test results may be missing or difficult to obtain. 31 
 32 
Protocol version: 7.0  33 
 34 
Keywords: primary care, urology, adult urology 35 
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INTRODUCTION 1 
Lower urinary tract symptoms (LUTS), such as frequent urination, a slow stream, and having to wake 2 
in the night to urinate, affect a significant proportion of older men and can lead to poor quality of life. 3 
Three common causes of LUTS are: instability of the bladder muscle (detrusor overactivity, DO), 4 
benign enlargement of the prostate gland causing bladder outlet obstruction (BOO), and weakness of 5 
the bladder muscle (detrusor underactivity, DU). These may be present individually or in 6 
combination.  7 
The reference standard test for investigation of LUTS, and thus diagnosis of DO, BOO and DU, is 8 
invasive urodynamics, which takes place in secondary care. Invasive urodynamics will be conducted 9 
rather than video urodynamics, which is in line with most contemporary national and international 10 
guidelines, and is sufficient to diagnose DO, BOO and DU, to which most non-complicated adult 11 
male LUTS can be attributed. It involves insertion of catheters into the patient’s bladder and rectum 12 
so that the behaviour of the bladder and outlet can be examined during filling and voiding. Owing to 13 
availability, complexity and cost, management decisions for men with LUTS are usually based on 14 
results from a combination of non- and minimally-invasive investigations instead. These include 15 
digital rectal examination (DRE) to assess prostate size, symptoms questionnaires, uroflowmetry, and 16 
measurement of post void residual. 17 
NICE Guidelines suggest that many men referred to specialist care with LUTS are eventually 18 
managed conservatively, and so could have remained within primary care. Male LUTS account for 19 
around four presentations per month in an average-sized General Practitioner (GP) practice. This rate 20 
of presentation, although high enough to represent a large burden on the National Health Service 21 
(NHS), makes it difficult for GPs to gain sufficient expertise to be confident about diagnosis and 22 
management. Further, GPs do not have access to simple tools giving an indication of the most likely 23 
cause of symptoms to guide treatment and management. Making such a tool available should improve 24 
treatment efficacy, standardise treatment, reduce unnecessary referrals, expedite referral of those 25 
requiring specialist care, and thus improve cost-effectiveness of NHS care.  26 
This led to the National Institute for Health Research (NIHR) releasing a 2015 health technology 27 
assessment (HTA) commissioned call (HTA number 15/40) seeking the delivery of: The development 28 
of a decision aid to help inform the choice of treatment or need for specialist referral for men 29 
presenting with lower urinary tract symptoms in primary care. Our team was successful in obtaining 30 
this funding and here we describe the protocol for our study: Primary care management of lower 31 
urinary tract symptoms in men: Development and validation of a diagnostic and clinical decision 32 
support tool (The PriMUS Study). 33 
Aims, Objectives and Outcome measures 34 
The PriMUS study aims to develop three diagnostic prediction models based on the results of simple 35 
clinical tests that can provide a useful prediction of urodynamic observations in men with LUTS. We 36 
will assess the diagnostic accuracy of these models, which will be implemented in software, along 37 
with management recommendation algorithms to form a clinical decision support tool for use in UK 38 
primary care. Our primary and secondary objectives and measures are outlined below. 39 
Primary Objectives 40 
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 Develop a statistical model to predict the likelihood of three urological conditions (bladder outlet 1 
obstruction, detrusor overactivity, detrusor underactivity) based on a series of non-invasive index 2 
tests, with invasive urodynamics as the reference standard.  3 
 Estimate the diagnostic accuracy of the above statistical model in an independent validation cohort. 4 
Secondary Objectives 5 
 Develop a series of patient management recommendations and thresholds for clinically useful 6 
diagnostic prediction by expert consensus and with reference to current clinical guidelines that 7 
map to the diagnoses predicted by the statistical model. 8 
 Combine the statistical model and management recommendations into an online tool that will 9 
form the prototype clinical decision support tool. 10 
 Complete a qualitative study to explore the feasibility of introducing the clinical decision support 11 
tool into primary care including potential acceptability to primary care staff and patients. 12 
 Collect NHS costs involved in delivering the new pathway and compare with cost of standard 13 
pathway calculated from NHS and other sources. 14 
 15 
Primary outcome 16 
Sensitivity and specificity of the diagnostic models for detecting detrusor underactivity, bladder outlet 17 
obstruction and detrusor over activity will be determined. The three conditions will be coded as binary 18 
outcomes (present/absent).   19 
 20 
Secondary outcomes   21 
 A patient management algorithm to guide initial treatment for men with LUTS. 22 
 A prototype online clinical decision support tool for use in primary care. 23 
 Qualitative summary of patients’ and clinicians’ views on the use of a LUTS clinical decision 24 
support tool in the primary care setting. 25 
 Costs / savings of implementation of the primary care LUTS clinical decision support tool both 26 
from a population and individual patient perspective. 27 
METHODS AND ANALYSIS 28 
Study design 29 
This is a prospective, diagnostic accuracy study involving the development and validation of a 30 
diagnostic tool. An internal pilot will assess primary care recruitment, acceptability of the reference 31 
test (invasive urodynamics) and data collection. Two cohorts of participants, one for development of 32 
the prototype diagnostic tool, and one for validation, will undergo a series of index tests (see Table 1) 33 
and the invasive reference standard (urodynamics) in approximately 90 GP practices across Newcastle 34 
Upon Tyne, Wales and Bristol (a list of study sites can be found on ISRCTN). There will also be 35 
qualitative data collection to explore acceptability of the urodynamics test, develop management 36 
recommendations for the tool and for user-testing of the prototype (see Table 2).   37 
 38 
Participants 39 
Adult men who consult their GP with one or more LUTS in UK primary care settings.  40 
Inclusion criteria 41 
 Men aged 16 years and over. 42 
 Men who present to their GP with a complaint of one or more bothersome lower urinary tract 43 
symptoms (this includes men on current treatment, but who are still symptomatic). 44 
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 Men able and willing to give informed consent for participation in study. 1 
 Men able and willing to undergo all index tests and reference test, and complete study 2 
documentation. 3 
Exclusion criteria 4 
 Men with neurological disease or injury affecting lower urinary tract function. 5 
 Men with LUTS considered secondary to current or past invasive treatment or radiotherapy 6 
for pelvic disease. 7 
 Men with contraindications to urodynamics such as heart valve or joint replacement surgery 8 
within the last three months, or immunocompromised/immunosuppressed men. 9 
 Men with indwelling urinary catheters or who carry out intermittent self-catheterisation. 10 
 Men whose initial assessment suggests that clinical findings are suggestive of: 11 
o Prostate or bladder cancer according to standard NHS cancer pathways. If later 12 
deemed unlikely, they become eligible for study participation. 13 
o Recurrent or persistent symptomatic urinary tract infection (UTI). If UTI is 14 
successfully treated but LUTS remain, they become eligible for study participation. 15 
o Urinary retention, for example palpable bladder after voiding. 16 
 Men unable to consent in English or Welsh where a suitable translator is not available. 17 
 18 
Test Selection 19 
Test selection, including the reference standard, was informed by a systematic review included in the 20 
relevant NICE guideline CG97[1] updated with a study-specific unpublished selective review by our 21 
group in 2015, the judgement of the expert clinical members of the study team, and the stipulations of 22 
the funding commissioning brief. All participants undergo all tests, which are a combination of: 23 
 Tests carried out for eligibility assessment prior to enrolment, as described above. 24 
 Tests carried out at participant visits to a primary or secondary care location for the purpose 25 
of the study following enrolment. 26 
 Tests carried out by the participant at home following enrolment. 27 
 28 
Index Tests 29 
Twelve potential parameters will be considered for the three logistic regression models. The 30 
investigations that provide these parameters are described in Table 1 below.  31 
Table 1. Index Tests and Input parameters that will be tested for use in the three logistic regression 32 
models. 33 
Test Result Input parameters that will be tested for use 
in the three logistic regression models. 
(result or unit) 
Relevant demographics Age in years  Age (years) 
Physical examination of 
abdomen 
Bladder palpable/not palpable 
N/A 
Digital rectal examination Prostate mild/moderate/severe enlargement 
Further assessment for prostate cancer 
required/not required 
Prostate size (enlarged/not enlarged) 
Prostate specific antigen PSA value – established thresholds for 
further assessment for prostate cancer 
(typically > 3 ng/ml) or benign enlargement 
(typically ≥ 1.5 ng/ml) 
Prostate specific antigen (ng/ml) 
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For clinical decision support tool: 
continuous variable in ng/mL 
International Consultation 
on Incontinence 
Questionnaire Male Lower 
Urinary Tract Symptoms 
Short Form (ICIQ M-
LUTS) 
Total score (0-52); Voiding symptom score 
(0-20), storage symptom score (0-24). 
Individual symptom bother scores scored 
separately from symptom severity scores (0-
130). 
Storage/incontinence symptoms sub-score 
Voiding symptoms sub-score 
International Prostate 
Symptom Score (IPSS) 
questionnaires. 
Total score (0-35) Storage/incontinence symptoms sub-score 
Voiding symptoms sub-score 
Bladder Diary Waking (day) time frequency, sleeping 
(night) time frequency, 24 hour voided 
volume, daytime voided volume, nocturnal 
voided volume, average volume voided each 
void, total urgency scores  
Mean urgency score 
Mean 24-hour fluid intake (ml) 
Uroflowmetry (Flowtaker) Maximum flow rate, voided volume against 
normal age-adjusted range. Single value in 
ml/s 
Median maximum flow rate (ml/s) 
Median voided volume (ml) 
Mean 24-hour frequency 
Mean nocturia 
Post void residual Residual volume against normal age-
adjusted range. Single value in ml 
Post void residual volume (ml) 
 1 
Reference Standard 2 
Our reference standard is invasive urodynamics, a test routinely carried out in a specialist care setting 3 
for the investigation of LUTS. For this study, it will be performed using portable equipment (Goby, 4 
Laborie, Mississauga, Canada) in either a primary or secondary care location, by specially-trained 5 
urodynamic nurses, according to International Continence Society (ICS) standards.[2] Safety 6 
information is covered in the Safety section below. 7 
Study Procedures 8 
Data Collection 9 
GPs, primary care nurses or an appropriately trained delegate will undertake the data collection relating 10 
to all the index tests. Specialist trained urodynamic nurses will undertake the data collection for the 11 
reference test.  12 
 13 
Data Management 14 
All data collection will be by electronic data capture using a bespoke database developed by the 15 
Cardiff University Centre for Trials Research Clinical Trials Unit (CTR), and paper copies of all case 16 
report forms (CRFs) will be available.  17 
 18 
Identification and Screening 19 
All men will be identified either opportunistically during a GP consultation, or by regular, pre-defined 20 
primary care database searches. They must undergo three screening tests prior to enrolment into the 21 
study; a physical examination of the abdomen (palpable bladder check), DRE and Prostate Specific 22 
Antigen (PSA) test. The latter two test results are accepted if they have undergone these investigations 23 
within the last six months.  24 
Protocol for PRImary care Management of lower Urinary tract Symptoms in men: Protocol for 
development and validation of a diagnostic and clinical decision support tool (The PriMUS Study). 
 Page 8 of 16 
 1 
Informed Consent 2 
Informed consent will be obtained in the first study visit (Study Visit Part A) prior to any study 3 
procedures by those suitably trained and on the delegation log. Eligible patients will be given time to 4 
consider before being asked to sign the consent form. Once consented, participants will be allocated a 5 
unique study number (participant ID). 6 
 7 
Separate informed consent will be taken for participation in the qualitative data collection.  8 
Withdrawal 9 
Patients will be notified that they can withdraw consent for their participation in the study at any time 10 
during the study period.  11 
 12 
Study Visit Part A 13 
Once informed consent is obtained, the remaining index tests will be collected. This includes a 14 
baseline assessment (collecting demographic information, relevant medication and medical history) 15 
and two self-reported questionnaires; IPSS and ICIQ. Participants will be given the bladder diary to 16 
complete for three days at home and instructed to bring this to their invasive urodynamic visit (Study 17 
Visit Part B).  18 
 19 
Study Visit Part B - Reference standard 20 
On arrival, the patient will be asked to pass urine into a flowmeter in private, after which a 21 
measurement of post void residual ultrasound (one of the index tests; see below) will be made. A dual 22 
lumen catheter (one channel to fill the bladder, and the other to measure intravesical pressure, Pves) 23 
will be inserted into the bladder via the urethra, and a single lumen catheter inserted into the rectum to 24 
measure abdominal pressure (Pabd). Detrusor pressure (Pdet), generated by the bladder muscle itself, is 25 
calculated by subtracting Pabd from Pves. 26 
Filling Phase 27 
The patient will be asked to bring their completed bladder diary (one of the index tests; see above) to 28 
their urodynamics appointment, providing the urodynamic nurse with an indication of their maximum 29 
bladder capacity. The patient’s bladder will be filled with sterile saline at a maximum rate of 30 
50 ml/min. They will be asked to report the first sensation of bladder filling, followed by the point at 31 
which they feel the normal desire to void, and finally the strong desire to void. At this point bladder 32 
filling will be stopped and provocation, in the form of running taps and asking the patient to cough, 33 
will be performed. 34 
 35 
Voiding Phase 36 
Following provocation, the patient will be given permission to void, marking the start of the voiding 37 
phase. Voided volume (Vvoid) and flow rate (Q) will be measured as they pass urine into the 38 
flowmeter. 39 
If either the filled or voided volumes are below 150 ml, the filling and voiding phases will be repeated 40 
once more using a maximum filling rate of 20 ml/min. 41 
Diagnostic Definitions 42 
Definition of our three target conditions will be based upon the following parameters measured during 43 
invasive urodynamics and subsequently read from a graphical representation of the test: 44 
1. Maximum detrusor contraction pressure during the filling phase. 45 
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2. Maximum flow rate during the voiding phase (Qmax). 1 
3. Detrusor pressure at the point of maximum flow rate (PdetQmax). 2 
If there are no detrusor contractions during filling, DO is not present. If there are any contractions 3 
(contraction pressure>0), DO is present. 4 
Diagnosis of BOO is based upon the bladder outlet obstruction index (BOOI), defined as 5 
PdetQmax-2*Qmax. BOO is present if BOOI>40, and absent if BOOI≤40. 6 
Diagnosis of DU is based upon the bladder contractility index (BCI), defined as PdetQmax+5*Qmax. 7 
DU is present if BCI<100, and absent if BCI≥100. 8 
Debrief process and monitoring process 9 
The urodynamic nurses will debrief the patient following the urodynamic procedure providing them 10 
with a post urodynamics leaflet and safety card. The urodynamic nurse will also instruct the patient 11 
that they will receive a 3 Day Follow Up Phone Call, to monitor for any related adverse events.  12 
 13 
3 Day Follow Up Phone Call 14 
The urodynamic nurses will contact the patient 3 days (+/- flexibility if phone call falls on weekend) 15 
after their urodynamic procedure to monitor for any adverse events and Serious Adverse Events 16 
(SAEs). Any SAEs are subsequently recorded by the urodynamic nurses and processed centrally by 17 
CTR. This process is outlined in the Safety Section (see below).  18 
 19 
Review Process 20 
Invasive urodynamics is a complex investigation and interpretation can be challenging. Further, 21 
because standard practice involves interaction between the reference and some index tests as 22 
described earlier, their primary interpretation in this study is not blinded. Therefore, a review process 23 
will be implemented to ensure the integrity of the reference standard. All studies will be second-read 24 
by a blinded reviewer to extract the three parameters above. If any of the resulting diagnoses differ 25 
between the nurse and this reviewer, the case will go to a second non-blinded reviewer who makes the 26 
final decision.  27 
Uroflowmetry* (Flowtaker) 28 
The patient is provided with the Flowtaker at the end of their invasive urodynamic visit. They will be 29 
provided with an information sheet on how to use this and instructed to not start this until given the 30 
greenlight to do so during their 3 Day Follow Up Phone Call. The Flowmeter will be given with a pre-31 
paid envelope for the patient to post back to their urodynamic nurse for data upload.  32 
GP Summary Report 33 
Once the reference and index tests have taken place, results are compiled into a report which is 34 
provided to GPs, along with a summary of relevant NICE-recommended managements,[1] to help 35 
inform management of the patient. 36 
 37 
6 Month Follow Up 38 
A review of the patient’s medical notes will take place 6 months after the patient’s treatment and 39 
management decision with the GP. This will include any changes to treatment, or management and 40 
whether they have since been referred to secondary care. Figure 1 depicts a flow diagram of the 41 
patient pathway.  42 
 43 
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[INSERT FIGURE 1 HERE] 1 
 2 
Safety and Pharmacovigilance 3 
Invasive urodynamics has the potential to cause adverse events. A medical doctor will be required on 4 
site whilst the test is taking place. Due to a 5% risk of a urinary tract infection,[3] the urodynamic 5 
nurse will also provide the patient with a post-urodynamics debrief sheet following the test, informing 6 
them on the importance of drinking plenty of water for 24 hours following the test, how to identify 7 
signs of an infection, and to seek medical care if they suspect they have one. 8 
 9 
Adverse events will be captured by the urodynamic nurses, either during Study Visit Part B, or during 10 
the 3 day follow up phone call. For serious adverse events (SAEs), an assessment of causality 11 
between the event and the study intervention, and the expectedness of the event, will be carried out by 12 
the carried out by the PI, or delegated urodynamic nurse, and then independently by a clinical 13 
reviewer. If the clinical reviewer classes the event as probably or definitely caused by the intervention, 14 
it will be classified as a serious adverse reaction.  15 
Sample Size 16 
Sample size calculations were carried out separately for the model development and validation 17 
cohorts. For both we used estimated prevalences for DO, BOO and DU of 57%, 31% and 16% 18 
respectively based on previous literature[4,5] and clinical expertise. 19 
 20 
Development Cohort 21 
The sample size for developing our predictive models was based on a rule of thumb suggesting that 22 
five events per variable are required.[6] We chose a sample size of 350 to allow at least 11 variables in 23 
each model. This was driven by our lowest estimated prevalence of 16% for DU, giving 56 events 24 
(DU diagnoses). 25 
Validation Cohort 26 
The sample size for the validation cohort was chosen to ensure that estimates of test accuracy are 27 
made with adequate precision. We deem sensitivity and specificity of 75% to be the minimum 28 
clinically useful performance. We chose a sample size of 325, giving estimates of sensitivity of 75% 29 
to within 8%, 10% and 14% for DO, BOO and DU respectively, based on ‘positive’ samples of 185, 30 
101 and 52, and estimates of specificity of 75% to within 8%, 7% and 6%, based on ‘negative’ 31 
samples of 140, 224 and 273. Better sensitivity and specificity will give narrower confidence 32 
intervals. 33 
Attrition 34 
In order to allow an attrition rate of 20-25%, the resulting total of 675 was increased to give a final 35 
sample size of 880.  36 
STATISTICAL ANALYSIS 37 
Model development will be performed using results from the first 350 datasets, and external model 38 
validation performed using the subsequent 325 datasets. 39 
Model Development 40 
Candidate predictor variables will be selected from those listed in Table 1. Their selection has been 41 
informed by subject knowledge using literature review and expert judgement. As predictor 42 
distributions should be wide to facilitate reliable predictions, we will explore the distribution of each 43 
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predictor prior to selection. Relationships between predictors will also be investigated; where 1 
indicated we will group related variables into a composite variable or exclude if highly correlated with 2 
other variables. Candidate predictors will not be selected based on univariable analyses; this practice 3 
is discouraged because predictors that may be important in a multivariable model can be missed and 4 
may also lead to overoptimistic models. Therefore, all selected candidate predictor variables will be 5 
included in the multivariable logistic regression models without evaluations of association between 6 
outcome and predictor and assessment of statistical significance. To gain maximum diagnostic 7 
information, continuous variables will not be categorised. We will allow for non-linearity by using a 8 
multivariable fractional polynomial (MFP) approach to identify appropriate transformations. This may 9 
lead to the inclusion of non-linear terms in the models thus increasing the number of variables in the 10 
models.  Using multiply imputed data and Rubin’s rule, we will develop each model using backward 11 
elimination with a p value of 0.157 to select predictors for inclusion in each model. We chose this p 12 
value because it is known to be a good proxy for the Akaike information criterion (AIC) approach. If 13 
the repeated use of Rubin’s rule is computationally challenging, we will use the approximation to 14 
Rubin’s rule recommended by Wood et al (2008).[7] 15 
Model Validation 16 
The predictive performance of each model will be assessed in terms of discrimination, that is the 17 
ability to distinguish between those who do or do not have a particular diagnosis, and calibration 18 
meaning agreement between predicted and observed probabilities. Discriminative ability will be 19 
assessed using the c-index and its 95% confidence intervals. For a logistic model, this is equivalent to 20 
the area under the ROC curve (AUC). Calibration will be evaluated in two ways. Calibration plots of 21 
average observed probability against predicted probability will be used to visually assess calibration. 22 
Within each quintile or decile of predicted probability (depending on the distribution of data), the 23 
average predicted probability will be compared with the corresponding observed proportions. We will 24 
also quantify calibration by estimating the calibration slope of the prognostic index (linear predictor) 25 
using logistic regression with the linear predictor as the covariate.  26 
The apparent c-index and calibration slope will be estimated for each model. Bootstrapping will be 27 
used for internal validation to assess model overfitting and optimism. For each model, we will obtain 28 
100 bootstrap samples from each imputed dataset and repeat the variable selection process. The 29 
optimism is the difference between the c-index from the bootstrap sample and that from the original 30 
imputed dataset. The average optimism will be determined across bootstrap samples and imputed 31 
datasets, and the optimism-adjusted c-index will be calculated by subtracting the average optimism 32 
from the apparent c-index of the original model. Similarly, we will obtain the optimism adjusted 33 
calibration slope. The optimism-adjusted calibration slope will be used as the uniform shrinkage 34 
factor to correct a model. 35 
We will externally validate the models and calculate performance statistics (c-index and calibration 36 
slope) using the validation cohort. The value for the calibration slope should ideally be one signifying 37 
perfect agreement between the predicted probabilities and the observed probabilities. A calibration 38 
slope < 1 indicates that a model over-predicts while a calibration slope > 1 indicates under prediction. 39 
From the qualitative research we will ascertain distributions of probability (risk) thresholds for 40 
clinical usefulness of the prediction in guiding treatment of each condition. The sensitivity and 41 
specificity (and their corresponding 95% confidence intervals), will be calculated for these risk 42 
thresholds and plotted on an ROC plot for each model.  43 
Missing Data 44 
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Patterns of missing data will be investigated to infer the ease with which each parameter can be 1 
obtained in practice. In the event of missing data, multiple imputation by chained equations[8] will be 2 
used to impute missing values in order to avoid bias and make best use of the data. 3 
 4 
SECONDARY SUB-STUDIES 5 
Table 2. Secondary Sub-Studies 6 
Qualitative Studies Details 
Patient and Clinician 
Acceptability Interviews – 
Internal Pilot Phase 
 
During the pilot phase we will conduct semi-structured qualitative interviews 
(n=30-40) with patients (consenting and declining entry to the main study) 
and participating clinicians to assess the acceptability of the urodynamic 
procedure and PriMUS Study, as part of our progression criteria. Interview 
schedules will be developed in discussion with clinician and patient 
representatives of the Study Management Group (SMG). Interview guides 
will broadly explore: practicality and acceptability of conducting urodynamic 
investigations (and experiences of patient participants); reactions to and 
experiences of the study processes (including barriers/facilitators). An 
iterative approach will be taken, so that schedules can be refined to further 
explore unanticipated themes that arise during data collection.  Interview 
transcripts will be entered into NVivo qualitative analysis software and 
analysed using Framework Analysis (using key topic areas as the 
framework).[9] Data will be used to inform strategies that will maximise 
recruitment and retention. 
 
Development of 
Management 
Recommendations 
 
Algorithms are required to link outputs from the statistical models, which will 
be likelihoods of each target condition, with patient management 
recommendations to form the clinical decision support tool. The starting point 
will be recommendations from the relevant NICE clinical guideline. 
Qualitative work with urologists will support the development of these 
management recommendations, through posing a range of clinical case 
scenarios to urologists using interview and questionnaire methodologies 
(n=15-20). Urologists will be asked to how they would manage these 
scenarios, with a focus on thresholds for treatment and strategies for multiple 
diagnoses. 
 
Tool Feasibility Assessment 
 
The aim of the user-testing phase will be to build on the interviews conducted 
as part of the pilot phase evaluation to assess GPs’ attitudes and reactions to 
the prototype clinical decision support tool. GPs (n=10-12) will be sent the 
tool prior to the semi-structured telephone interview and asked to use it. The 
interview schedule will explore the following: ease of use, content, design, 
and perceived acceptability and feasibility of using the tool in routine primary 
care settings (allowing succinct exploration of the prototype tool). Interview 
transcripts will be entered into NVivo qualitative analysis software and 
analysed using Framework Analysis (using key topic areas as the 
framework).[9] Feedback will be used to improve and refine the tool.  
 
 7 
STUDY MANAGEMENT 8 
The study is sponsored by Cardiff University, coordinated by CTR and co-led by The Newcastle upon 9 
Tyne Hospitals NHS Foundation Trust (NuTH). The other partner organisations will be Birmingham 10 
University, University of Bristol, and North of England Commissioning Support.   11 
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Study management Group 1 
The Study Management Group (SMG) will meet monthly throughout the course of the study and will 2 
include the Chief Investigators, co-applicants, collaborators, study manager, data manager and 3 
administrator. Two patient representatives will also attend and contribute to the conception, design 4 
and management of the study, as well as patient-facing materials. SMG members will be required to 5 
sign up to the remit and conditions as set out in the SMG Charter.  6 
 7 
Study Steering Committee 8 
An independent Study Steering Committee (SSC) consisting of an independent chairperson, two 9 
independent members and two patient representatives will provide oversight of The PriMUS Study. 10 
Instead of a separate Independent Data Monitoring Committee (IDMC), the SSC will also provide 11 
oversight of all matters relating to patient safety and data quality. Members will be required to sign up 12 
to the remit and conditions as set out in the SSC Charters and will meet annually.  13 
 14 
ETHICS AND DISSEMINATION 15 
Research approvals 16 
The Wales REC 6 has approved the study (17/WA/0155) on the 20th June 2017 and subsequent R&D 17 
Approval for Wales on 21st August 2017 and HRA Approval on 23rd August 2017. 18 
 19 
All study participants will give informed consent before taking part (see earlier). 20 
 21 
The following substantial amendments were made to the trial and were communicated to all trial sites:  22 
Substantial Amendment 1 (3rd October 2017); Substantial Amendment 2 (10th January 2018); 23 
Substantial Amendment 3 (20th April 2018); Substantial Amendment 4 (26th February 2019); 24 
Substantial Amendment 5 (6th June 2019); Substantial Amendment 6 (6th September 2019)  25 
 26 
The study has the following registration: ISRCTN10327305 27 
 28 
Dissemination plan 29 
Following completion of the study, a final report will be prepared for the National Institute of Health 30 
Research (NIHR) Journal series. A paper describing the primary results will be submitted to a high 31 
impact, international, peer-reviewed journal. Qualitative studies and sub-studies will also be 32 
submitted for publication. We will present our findings at national and international scientific 33 
meetings. 34 
With the assistance of our collaborators and lay representatives we will disseminate the study findings 35 
to a wide NHS and general audience and promote uptake of outputs into clinical care. This will 36 
include presentations at meetings and written executive summaries for key stakeholder groups such as 37 
Primary Care Trusts, Secondary Care Trusts, Health Boards, Royal Colleges, Medical Schools, and 38 
relevant patient groups. 39 
All publications and presentations relating to the study will be authorised by the SMG in accordance 40 
with the study’s publication policy. 41 
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